Form 4: Dianthus CFO Ryan Savitz Executes 10b5-1 Plan

Dianthus Therapeutics' CFO and CBO, Ryan Savitz, exercised stock options and sold 20,000 shares of common stock for a significant profit, pursuant to a pre-arranged trading plan.

Summary

• Ryan Savitz, CFO & CBO of Dianthus Therapeutics, Inc. (DNTH), executed a transaction on December 4, 2025.
• Savitz acquired 20,000 shares of common stock by exercising stock options at a price of $8.44 per share, totaling $168,800.
• Immediately following the exercise, Savitz sold all 20,000 acquired shares at a weighted average price of $45.18 per share, generating total proceeds of $903,600.
• The sales were conducted in multiple transactions with prices ranging from $45.00 to $45.43 per share.
• These transactions were carried out under a Rule 10b5-1 trading plan adopted by Savitz on March 31, 2025.
• After these transactions, Savitz directly owns 0 shares of common stock and beneficially owns 84,766 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While insider selling can sometimes be viewed negatively, this transaction was pre-planned under a 10b5-1 plan, reducing the immediate negative signal. The significant profit realized by the CFO also indicates a healthy appreciation in the company's stock value, which is a positive for shareholders.

Positives

• The reporting person realized a substantial profit of $734,800 from the exercise and sale of shares, indicating a significant increase in the company's stock value since the options were granted.
• The transaction was executed under a Rule 10b5-1 trading plan, which suggests a pre-planned sale rather than a reaction to immediate company news, potentially mitigating negative perceptions of insider selling.

Negatives

• An insider selling a significant number of shares, even under a 10b5-1 plan, could be interpreted by some investors as a lack of confidence in the company's near-term growth prospects, although this is not explicitly stated.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the insider's profitable transaction as a positive indicator of the company's stock performance, or with slight caution due to the sale of shares.
• Employees: May see the executive's ability to profit from stock options as a positive aspect of the company's compensation structure and growth.

Key Dates

Keywords

Dianthus Therapeutics, DNTH, Ryan Savitz, CFO, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Beneficial Ownership